Coronary Heart Disease in Patients With Diabetes. Part II: Recent Advances in Coronary Revascularization

Journal of the American College of Cardiology

Volumn 49, Issue 6, 2007, Pages 643-656

  Berry, Colin ^a   Tardif, Jean Claude ^a   Bourassa, Martial G ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; HIRULOG; INSULIN; PACLITAXEL; PEXELIZUMAB; RAPAMYCIN; TIROFIBAN;

BODY MASS; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DRUG ELUTING STENT; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REGISTER; RESTENOSIS; REVIEW; SURGICAL PATIENT; THROMBOSIS; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

EID: 33846840766     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.09.045     Document Type: Review

References (83)

1. Hammoud T., Tanguay J.F., and Bourassa M.G. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 36 (2000) 355-365
2. Mak K.H., and Faxon D.P. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 24 (2003) 1087-1103
3. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularization. JAMA 293 (2005) 1501-1508
4. King S.B., Kosinski A.S., Guyton R.A., Lembo N.J., and Weintraub W.S. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 35 (2000) 1116-1121
5. Ahmed J.M., Hong M.K., Mehran R., et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 36 (2000) 1186-1193
6. Bourassa M.G. Bypass Angioplasty Revascularization Investigation (BARI). In: Morrison D.A., and Serruys P. (Eds). High-Risk Cardiac Revascularization and Clinical Trials (2002), Martin Dunitz, London 145-161
7. Alderman E.L., Brooks M.M., Bourassa M.G., et al. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 35 (2000) 1122-1129
8. Brooks M.M., Jones R.H., Bach R.G., et al. Predictors of morbidity and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. Circulation 101 (2000) 2682-2689
9. Alderman E., Bourassa M.G., Brooks M.M., et al. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
10. Detre K.M., Guo P., Holubkov R., et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 99 (1999) 633-640
11. Kip K.E., Alderman E.L., Bourassa M.G., et al. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation 105 (2002) 1914-1920
12. Detre K.M., Lombardero M.S., Brooks M.M., et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N Engl J Med 342 (2000) 989-997
13. Alderman E.L., Kip K.E., Whitlow P.L., et al. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 44 (2004) 766-774
14. Kurbaan A.S., Bowker T.J., Ilsley C.D., Sigwart U., and Rickards A.F. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 87 (2001) 947-950
15. van Domburg R.T., Foley D.P., Breeman A., van Herwerden L.A., and Serruys P.W. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty: twenty-year clinical outcome. Eur Heart J 23 (2002) 543-549
16. Halon D.A., Merdler A., Flugelman M.Y., et al. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol 85 (2000) 1420-1426
17. Abizaid A., Costa M.A., Centemero M., et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104 (2001) 533-538
18. Serruys P.W., Ong A.T.L., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005) 575-581
19. Sigwart U., Stables R.H., Booth J., et al. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 360 (2002) 965-970
20. Rodriguez A., Bernardi V., Navia J., et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. J Am Coll Cardiol 37 (2001) 51-58
21. Rodriguez A.E., Baldi J., Pereira C.F., et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 46 (2005) 582-588
22. Sedlis S.P., Morrison D.A., Lorin J.D., et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 40 (2002) 1555-1566
23. Srinivas V.S., Brooks M.M., Detre K.M., et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation 106 (2002) 1627-1633
24. Williams D.O., Holubkov R., Yeh W.L., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 102 (2000) 2945-2951
25. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
26. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
27. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
28. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
29. Finn A.V., Palaclos I.F., Kastrati A., and Gold H.K. Drug-eluting stents for diabetes mellitus: a rush to judgment?. J Am Coll Cardiol 45 (2005) 479-483
30. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
31. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
32. Ong A.T.L., Serruys P.W., Mohr F.W., et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 151 (2006) 1194-1204
33. Park SJ, Leon M. COMparison of Bypass Surgery and AngioplasTy Using Sirolimus-eluting Stent in Patients With Unprotected Left Main Coronary Artery Disease. 2006. Available at: http://www.tctmd.com/csportal/appmanager/tctmd/main? Accessed March 7, 2006.
34. Sobel B.E., Frye R., and Detre K.M. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 107 (2003) 636-642
35. Kapur A., Malik I.S., Bagger J.P., et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 149 (2005) 13-19
36. Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM). Available at: http://www.clinicaltrials.gov/ct/show/NCT00086450?order = 1. Accessed March 8, 2006.
37. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
38. Mehta S.R., Cannon C.P., Fox K.A.A., et al. Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
39. Herlitz J., Wognsen G.B., Karlson B.W., et al. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 11 (2000) 339-346
40. Whang W., and Bigger J.T. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from the CABG Patch Trial database. J Am Coll Cardiol 36 (2000) 1166-1172
41. Costa M.A., Carere R.G., Lichtenstein S.V., et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS). Circulation 104 (2001) 2689-2693
42. Jaffe A.S. Can creatine kinase MB levels predict mortality after cardiac surgery?. Nat Clin Pract Cardiovasc Med 2 (2005) 280-281
43. Verrier E.D., Shernan S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291 (2004) 2319-2327
44. Schwartz L., Kip K.E., Frye R.L., Alderman E.L., Schaff H.V., and Detre K.M. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106 (2002) 2652-2658
45. Newman M.F., Kirchner J.L., Phillips-Bute B., et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 344 (2001) 395-402
46. McKhann G.M., Grega M.A., Borowicz L.M., et al. Is there cognitive decline 1 year after CABG?. Comparison with surgical and nonsurgical controls. Neurology 65 (2005) 991-999
47. Herlitz J., Caidahl K., Wiklund I., et al. Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complications 14 (2000) 314-321
48. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294 (2005) 2446-2454
49. Mathew V., Clavell A.L., Lennon R.J., Grill D.E., and Holmes D.R. Percutaneous coronary interventions in patients with prior coronary artery bypass surgery: changes in patient characteristics and outcome during two decades. Am J Med 108 (2000) 127-135
50. Hong M.K., Mehran R., Dangas G., et al. Are we making progress with percutaneous saphenous vein graft treatment?. A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol 38 (2001) 150-154
51. Cole J.H., Jones E.L., Craver J.M., et al. Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol 40 (2002) 1968-1975
52. Anderson H.V., SHAW R.E., Brindis R.G., et al. A contemporary overview of percutaneous coronary interventions: the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 39 (2002) 1096-1103
53. Mathew V., Gersh B.J., Williams B.A., et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation 109 (2004) 476-480
54. Laskey W.K., Selzer F., Vlachos H.A., et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 90 (2002) 1062-1067
55. Bartholomew B.A., Harjai K.J., Dukkipati S., et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93 (2004) 1515-1519
56. Ricciardi M.J., Davidson C.J., Gubernikoff G., et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 145 (2003) 522-528
57. Harjai K.J., Stone G.W., Boura J., et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 91 (2003) 1041-1045
58. Fuchs S., Kornowski R., Mehran R., et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 85 (2000) 1077-1082
59. Castagna M.T., Mintz G.S., Ohlmann P., et al. Incidence, location, magnitude, and clinical correlates of saphenous vein graft calcification: an intravascular ultrasound and angiographic study. Circulation 111 (2005) 1148-1152
60. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
61. Mercado N., Boersma E., Wijns W., et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 38 (2001) 645-652
62. West N.E.J., Ruygrok P.N., Disco C.M.C., et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109 (2004) 867-873
63. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
64. Corpus R.A., George P.B., House J.A., et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43 (2004) 8-14
65. Mazeika P., Prasad N., Bui S., and Seidelin P.H. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 145 (2003) 1013-1021
66. Straumann E., Kurz D.J., Muntwyler J., et al. Admission glucose concentrations independently predict early and later mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention. Am Heart J 150 (2005) 1000-1006
67. Gurm H.S., Brennan D.M., Booth J., Tcheng J.E., Lincoff A.M., and Topol E.J. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 90 (2002) 42-45
68. Gruberg L., Weissman N.J., Waksman R., et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?. J Am Coll Cardiol 39 (2002) 578-584
69. Gurm H.S., Whitlow P.L., Kip K.E., et al. The impact of body mass index on short- and long-term outcomes in patients undergoing coronary revascularization: insights from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 39 (2002) 834-840
70. Gruberg L., Mercado N., Milo S., et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: the obesity paradox II?. Am J Cardiol 95 (2005) 439-444
71. Aronson D., Goldberg A., Roguin A., et al. Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina. Atherosclerosis 185 (2006) 137-142
72. Furnary A.P., Gao G.Q., Grunkemeier G.L., et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125 (2003) 1007-1021
73. Bradshaw P.J., Jamrozik K., Gilfillan I., and Thompson P.L. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 147 (2004) 1047-1053
74. Mehta S.R., Yusuf S., Peters R.J.G., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
75. Angiolillo D.J., Sabate M., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
76. Tcheng J.E., O'Shea J.C., Cohen E.A., et al. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
77. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
78. Roffi M., Moliterno D.J., Meier B., et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do tirofiban and ReoPro give similar efficacy outcomes trial (TARGET) 1-year follow-up. Circulation 105 (2002) 2730-2736
79. Mehilli J., Kastrati A., Schuhlen H., et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3627-3635
80. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., and Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35 (2000) 922-928
81. Roffi M., Chew D.P., Mukherjee D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 104 (2001) 2767-2771
82. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
83. Takagi T., Yamamuro A., Tamita K., et al. Impact of Troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89 (2002) 318-322